Advice
following a resubmission considered under the orphan medicine process:
obinutuzumab (Gazyvaro®) is not recommended for use within NHSScotland.
Indication under review: obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.
In a phase III study, obinutuzumab decreased the risk of disease progression compared with another monoclonal antibody in a subgroup of patients with previously untreated advanced follicular lymphoma.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- obinutuzumab (Gazyvaro)
- SMC ID:
- SMC2015
- Indication:
- In combination with chemotherapy, followed by maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma (FL).
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 10 September 2018